- Login
- Register
- Home/Current Issue
- About the journal
- Editorial board
- Online submission
- Instructions for authors
- Subscriptions
- Foundation Acta Endocrinologica
- Archive
- Contact
Romanian Academy
The Publishing House of the Romanian Academy
ACTA ENDOCRINOLOGICA (BUC)
The International Journal of Romanian Society of Endocrinology / Registered in 1938in Web of Science Master Journal List
Acta Endocrinologica(Bucharest) is live in PubMed Central
Journal Impact Factor - click here.
Showing 1 - 2 of 2
-
Case Report
Radojkovic D, Stojanovic M., Pesic M., Radojkovic M., Radenkovic S., Radjenovic T.P., Stevic M., Stankovic I
Clinically “silent” giant pheochromocytoma. case reportActa Endo (Buc) 2013 9(1): 121-129 doi: 10.4183/aeb.2013.121
AbstractContext. Clinically „silent“ pheochromocytomas are very rare tumors. Objective. We present a patient with incidentally discovered, asymptomatic benign pheochromocytoma and discuss its presentation and management. Conclusion. Considering the increasing incidence of adrenal incidentalomas and, therefore, pheochromocytomas too, every incidentally found adrenal mass has to be carefully examined regardless of its clinical presentation in order to prevent fatal oversight of possible secreting nature and/or malignant potential of the lesion and to ensure an adequate curable treatment. -
Clinical review/Extensive clinical experience
Soldat-Stankovic V, Popovic Pejicic S, Stankovic S, Jovanic J, Bjekic-Macut J, Livadas S, Ognjanovic S, Mastorakos G, Micic D, Macut D
The Effect of Myoinositol and Metformin on Cardiovascular Risk Factors in Women with Polycystic Ovary Syndrome: a Randomized Controlled TrialActa Endo (Buc) 2021 17(2): 241-247 doi: 10.4183/aeb.2021.241
AbstractContext. Cardiovascular risk is increased in women with polycystic ovary syndrome (PCOS). Do insulin sensitizing agents such as metformin (MET) and myoinositol (MI) ameliorate biomarkers of cardiovascular risk? Objective. To compare the effects of MET and MI on blood pressure, lipid profile and high sensitive C-reactive protein (hs-CRP) in women with PCOS in respect to their body mass index (BMI). Design. Open label, parallel randomized, single center study. Subjects and Methods. Sixty six women with PCOS (33 normal-weight and 33 overweight/obese) were randomized to either MI (4 g/day) or MET (1500 mg/day) for a period of 6 months. Serum concentration of hormones, lipid profile, oxidized LDL (ox-LDL), hs-CRP, blood pressure measurement and clinical assessment of BMI, waist circumference (WC) and Ferriman Gallwey score (FG score) were performed before and after treatment. Results. Thirty patients in each group completed the trial. Compared with MET, MI significantly decreased diastolic blood pressure (DBP) (p=0.036) and significantly increased serum hs-CRP (p=0.043). No differences between groups in total cholesterol (TC), HDL-cholesterol, LDLcholesterol, ox-LDL and triglycerides were reported after 6 months. Treatment with MI reduced BMI (p=0.037), WC (p=0.005), DBP (p=0.021) and TC (p=0.008). During MET treatment a significant decrease in BMI (p=0.005), WC (p=0.004), FG score (p=0.001), testosterone (p=0.013) and free androgen index (FAI) (p=0.006) was observed. Conclusions. Our study showed an advantage of MI in reduction of DBP and TC thus predicting favorable metabolic and cardiovascular outcomes in PCOS women. MET more effectively decrease indices of hyperandrogenism.
Showing 1 - 2 of 2